A clinical report published on Medscape on June 22, 2026 presents evidence that adding cytoreductive surgery — the surgical removal of residual tumor masses — during tyrosine kinase inhibitor (TKI) drug therapy may extend survival in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).
The underlying study, published online June 11, 2026, in the International Journal of Cancer, was led by Dr. Fedor Moiseenko of the N.P. Napalkov Cancer Center in St. Petersburg, Russia, and colleagues. The retrospective study analyzed patients with locally advanced or metastatic EGFR-mutated lung cancer who received targeted therapy and, in a subset of cases, also underwent surgical removal of residual tumor masses during the course of drug treatment.
